52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Oxford BioMedica Plc Says Andrew Heath Will Be Retiring As Non-Executive Director
Oxford Biomedica Upgrades Financial Guidance For Supply Agreement With AstraZeneca For Manufacture Of COVID-19 Vaccine
Oxford BioMedica FY Operating Loss 5.7 Million Stg
Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Biotechnology & Drugs
Windrush Court, Transport Way
Roch Frederic Doliveux
Non-Executive Chairman of the Board
Chief Executive Officer, Executive Director
Deputy Chair and Senior Independent Non-Executive Director
Chief Financial Officer, Executive Director
Chief Operating Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.
Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca after the drugmaker commissioned more batches from the company in the second half of 2021.
AstraZeneca has expanded its agreement with cell therapy firm Oxford Biomedica to mass-produce its COVID-19 potential vaccine, as it looks to scale-up supply ahead of a possible U.S. fast-track approval.
AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a possible fast-track approval from the United States.
AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs...
* OXFORD BIOMEDICA - PLACING AT 800 PENCE PER/SHARE RAISING GROSS PROCEEDS OF £40 MILLION FOR CO, ABOUT £38.25 MILLION NET OF EXPENSES Source text for Eikon: Further company coverage:
* PROXY ADVISORY FIRM PIRC RECOMMENDS A.G. BARR SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO APPROVE REMUNERATION POLICY
* OXFORD BIOMEDICA PLC - PROPOSED PLACING OF NEW ORDINARY SHARES
* OXFORD BIOMEDICA PLC - UPDATE ON SANOFI OPHTHALMOLOGY PROGRAMMES
Oxford Biomedica has signed a new manufacturing agreement with a group backed by the UK government to help it scale up production of AstraZeneca's potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.
* OXFORD BIOMEDICA PLC - SIGNS FIVE YEAR COLLABORATION AGREEMENT WITH VACCINES MANUFACTURING AND INNOVATION CENTRE
Gene and cell therapy firm Oxford Biomedica said on Monday it signed a new manufacturing agreement to help it scale up production of AstraZeneca's potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.
Britain's AstraZeneca has clinched expanded regulatory backing for two medications, including one for blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.
Gene and cell therapy firm Oxford Biomedica plc said on Monday it had appointed French pharmaceutical industry veteran Roch Doliveux as its non-executive chairman, as it eyes a potentially major role in producing coronavirus vaccine.
* OXFORD BIOMEDICA - ROCH DOLIVEUX WILL BECOME NON-EXECUTIVE CHAIRMAN OF GROUP WITH EFFECT FROM 24 JUNE 2020 Source text for Eikon: Further company coverage:
AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.
Britain's Oxford BioMedica has agreed with AstraZeneca to manufacture the drugmaker's experimental COVID-19 vaccine, the cell therapy company said on Thursday.
* OXFORD BIOMEDICA PLC - SIGNED A ONE YEAR CLINICAL & COMMERCIAL SUPPLY AGREEMENT WITH ASTRAZENECA UK LTD
* OXFORD BIOMEDICA PLC - OXB RECEIVES APPROVAL FOR FIRST TWO OXBOX SUITES Source text for Eikon: Further company coverage:
* JOINED CONSORTIUM TO RAPIDLY DEVELOP, SCALE-UP AND MANUFACTURE A POTENTIAL VACCINE CANDIDATE FOR COVID-19 Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.